The February 2026 HHS announcement on peptide reclassification
HHS made a significant announcement in February 2026 about returning seven peptides from Category 2 to Category 1. But “proposed” and “effective” are different things. Here’s where the process actually stands.
TL;DR
- In February 2026, the Department of Health and Human Services proposed returning seven peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, and Semax — from Category 2 back to Category 1 under the FDA’s 503A compounding framework.
- This proposal does not immediately make these peptides available via licensed compounding pharmacies. It initiates a formal rulemaking process that requires Federal Register publication, a public comment period, and final FDA action.
- The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet in July 2026 to further review these compounds — a step in the formal pathway.
What it is
In February 2026, the Department of Health and Human Services issued an announcement signaling its intent to propose returning seven specific peptides from Category 2 classification to Category 1 under Section 503A of the Federal Food, Drug, and Cosmetic Act. The seven compounds named were BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, and Semax — all of which had been placed in Category 2 following the PCAC vote in 2023. The announcement was significant as a statement of policy direction, but it was an announcement of intent, not an immediately binding regulatory change.
How it works
The procedural pathway for reclassifying a peptide from Category 2 to Category 1 under the FDA’s 503A framework involves several steps. First, the FDA’s Pharmacy Compounding Advisory Committee reviews the nominated substance and provides a recommendation to the FDA Commissioner. This advisory committee recommendation is then reflected in a proposed rule or guidance document published in the Federal Register. The Federal Register publication triggers a required public comment period — typically 30 to 60 days — during which the public, industry, and healthcare organizations can submit written input. After the comment period closes, the FDA reviews the comments and publishes a final rule. Only after the final rule is published does the reclassification become legally effective. As of April 2026, the required Federal Register notice had not been published for these seven peptides.
Who asks about it
People come to this topic when they’ve seen news coverage of the HHS announcement and heard references to “seven peptides coming back” in podcasts or online discussions. The disconnect between “announcement” and “available now” is causing real confusion. Patients and clinicians asking whether BPC-157 or TB-500 can now be prescribed through a licensed 503A pharmacy — as of April 2026, the answer remains no.
What the research says
The scientific rationale cited in the HHS announcement drew in part on emerging human-safety data and pre-clinical research that had accumulated since the 2023 PCAC vote. For some of the seven peptides — particularly BPC-157, which has an extensive animal literature on tissue repair — the committee’s 2023 decision had been criticized by some researchers as premature given the volume of published preclinical data. The February 2026 announcement signaled that the agency was willing to re-evaluate those determinations in light of additional information. The PCAC meeting scheduled for July 2026 will be the formal forum for this review, and the committee’s recommendation will inform the next steps in the rulemaking process.
What to know before considering it
None of the seven peptides named in the February 2026 HHS announcement are currently available via licensed 503A compounding pharmacies as of the date of this article. Sourcing these compounds outside of licensed pharmacy channels does not carry the legal or quality-control protections of 503A compounding. Halftime Health does not provide Category 2 peptides and will update its formulary through licensed clinical channels when and if reclassification becomes legally effective.
The Halftime POV
The February 2026 announcement matters — it’s a meaningful signal about the direction of regulatory policy on peptides. But the distance between a policy signal and a clinical reality is real, and the responsible position is to describe that distance accurately. We’ll follow the Federal Register notices, the July 2026 PCAC meeting, and the final rule publication closely and update our content when the regulatory status formally changes.
Related reading:
FAQ
Q: What did the February 2026 HHS announcement actually say? A: The HHS announcement expressed the department’s intent to return several Category 2 peptides — including BPC-157, TB-500, KPV, and others — to Category 1 status. ‘Expressed intent’ is a preliminary policy signal, not a regulatory action. The actual status change requires a formal FDA Federal Register notice with a comment period before taking effect.
Q: Has the February 2026 HHS announcement changed current peptide access? A: No. As of April 2026, the formal Federal Register notice had not been published. Category 2 peptides remain Category 2 under the current regulatory framework. Any vendor claiming to dispense previously Category 2 peptides legally through 503A pharmacies before the formal notice is published is making a legally unsupported claim.
Q: When might Category 2 peptides become available? A: The timeline depends on FDA’s Federal Register process. After the HHS announcement, the next step is FDA publication of a proposed rule or notification, a public comment period (typically 30–60 days), and a final agency action. This process could take several months to over a year from the announcement date. Halftime Health will update this post when the status changes.
Disclaimer
As of April 2026, several peptides discussed in this article — including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, and Semax — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- HHS. Press Release on peptide reclassification proposal. February 2026. HHS.gov
- FDA. PCAC 2023 Meeting Summary. FDA.gov
- FDA. “Bulk Drug Substances That May Be Used in Compounding Under Section 503A.” FDA.gov
- Federal Register. PCAC Nominations and Proposed Rules (search “503A bulk drug substances”). FederalRegister.gov
